Control Group N = 138 | |||||||||
 | LoS ≤ 5 days | LoS 6–9 days | LoS ≥ 10 days | ||||||
 ASA grade 1 | n = 37 | 26 (70 %) | 9 (24 %) | 2 (5 %) | |||||
 ASA grade 2 | n = 83 | 45 (54 %) | 27 (35 %) | 11 (13 %) | |||||
 ASA grade 3 | n = 18 | 4 (22 %) | 6 (33 %) | 8 (44 %) | |||||
Intervention group N = 107 a | |||||||||
 ASA grade 1 | n = 21 | 14 (67 %) | 7 (33 %) | 0 | |||||
 ASA grade 2 | n = 61 | 35 (57 %) | 22 (36 %) | 4 (7 %) | |||||
 ASA grade 3 | n = 25 | 18 (72 %) | 2 (28 %) | 0 | |||||
Overall LoS for patients with ASA grade 1 | |||||||||
 | Mean LoS | SD | Range | Diff | Age \( \overset{\hbox{--} }{\mathrm{x}} \) (Median) | 95 % CI | P-value | ||
 Control Group | n = 37 | 5.65 | 2.97 | 18 days | 0.84 | 57 (58) | −0.58 | 2.26 | 0.28 |
 gPCC Group | n = 21 | 4.81 | 1.72 | 9 days | 67 (64) | ||||
Overall LoS for patients with ASA grade 2 | |||||||||
 | Mean LoS | SD | Range | Diff | Age \( \overset{\hbox{--} }{\mathrm{x}} \) (Median) | 95 % CI | P-value | ||
 Control Group | n = 83 | 6.65 | 3.81 | 25 days | 0.81 | 67 (67) | −0.3 | 1.93 | 0.15 |
 gPCC Group | n = 61 | 5.84 | 2.52 | 13 days | 76 (78) | ||||
Overall LoS for patients with ASA grade 3b | |||||||||
 | Mean LoS | SD | Range | Diff | Age \( \overset{\hbox{--} }{\mathrm{x}} \) (Median) | 95 % CI | P-value | ||
 Control Group | n = 18 | 11.50 | 9.36 | 40 days | 6.78 | 73 (73) | 2.94 | 10.62 | 0.001 |
 gPCC Group | n = 25 | 4.72 | 1.57 | 7 days | 69 (71) |